Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 2
2007 8
2009 5
2010 4
2011 8
2012 1
2013 3
2014 6
2015 14
2016 8
2017 12
2018 13
2019 11
2020 10
2021 13
2022 3
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics.
Tirier SM, Mallm JP, Steiger S, Poos AM, Awwad MHS, Giesen N, Casiraghi N, Susak H, Bauer K, Baumann A, John L, Seckinger A, Hose D, Müller-Tidow C, Goldschmidt H, Stegle O, Hundemer M, Weinhold N, Raab MS, Rippe K. Tirier SM, et al. Among authors: seckinger a. Nat Commun. 2021 Nov 29;12(1):6960. doi: 10.1038/s41467-021-26951-z. Nat Commun. 2021. PMID: 34845188 Free PMC article.
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, Delon C, Latzko M, Gianotti R, Lüoend R, Murr R, Hosse RJ, Harnisch LJ, Bacac M, Fauti T, Klein C, Zabaleta A, Hillengass J, Cavalcanti-Adam EA, Ho AD, Hundemer M, San Miguel JF, Strein K, Umaña P, Hose D, Paiva B, Vu MD. Seckinger A, et al. Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2. Cancer Cell. 2017. PMID: 28262554 Free article.
The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance.
Ovejero S, Viziteu E, Dutrieux L, Devin J, Lin YL, Alaterre E, Jourdan M, Basbous J, Requirand G, Robert N, de Boussac H, Seckinger A, Hose D, Vincent L, Herbaux C, Constantinou A, Pasero P, Moreaux J. Ovejero S, et al. Among authors: seckinger a. Front Immunol. 2022 Dec 9;13:983181. doi: 10.3389/fimmu.2022.983181. eCollection 2022. Front Immunol. 2022. PMID: 36569948 Free PMC article.
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.
Seckinger A, Majocchi S, Moine V, Nouveau L, Ngoc H, Daubeuf B, Ravn U, Pleche N, Calloud S, Broyer L, Cons L, Lesnier A, Chatel L, Papaioannou A, Salgado-Pires S, Krämer S, Gockel I, Lordick F, Masternak K, Poitevin Y, Magistrelli G, Malinge P, Shang L, Kallendrusch S, Strein K, Hose D. Seckinger A, et al. J Hematol Oncol. 2023 Dec 12;16(1):117. doi: 10.1186/s13045-023-01516-3. J Hematol Oncol. 2023. PMID: 38087365 Free PMC article.
High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders.
Köhrer S, Dittrich T, Schorb M, Weinhold N, Haberbosch I, Börmel M, Pajor G, Goldschmidt H, Müller-Tidow C, Raab MS, John L, Seckinger A, Brobeil A, Dreger P, Tornóczky T, Pajor L, Hegenbart U, Schönland SO, Schwab Y, Krämer A. Köhrer S, et al. Among authors: seckinger a. Leukemia. 2023 Dec;37(12):2468-2478. doi: 10.1038/s41375-023-02056-y. Epub 2023 Oct 11. Leukemia. 2023. PMID: 37821581 Free PMC article.
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma.
Mai EK, Huhn S, Miah K, Poos AM, Scheid C, Weisel KC, Bertsch U, Munder M, Berlanga O, Hose D, Seckinger A, Jauch A, Blau IW, Hänel M, Salwender HJ, Benner A, Raab MS, Goldschmidt H, Weinhold N. Mai EK, et al. Among authors: seckinger a. Blood Cancer J. 2023 Jan 4;13(1):1. doi: 10.1038/s41408-022-00772-9. Blood Cancer J. 2023. PMID: 36599831 Free PMC article. Clinical Trial.
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Maes K, De Bruyne E, Menu E, De Veirman K, Moreaux J, Vanderkerken K, Seckinger A, Hose D. Emde-Rajaratnam M, et al. Among authors: seckinger a. Front Immunol. 2023 Nov 15;14:1286700. doi: 10.3389/fimmu.2023.1286700. eCollection 2023. Front Immunol. 2023. PMID: 38035078 Free PMC article.
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial.
Salwender H, Weinhold N, Benner A, Miah K, Merz M, Haenel M, Jehn C, Mai E, Menis E, Blau I, Scheid C, Hose D, Seckinger A, Luntz S, Besemer B, Munder M, Brossart P, Glass B, Lindemann HW, Weisel K, Hanoun C, Schnitzler P, Klemm S, Goldschmidt H, Raab M, Elmaagacli A. Salwender H, et al. Among authors: seckinger a. Hematology. 2024 Dec;29(1):2320006. doi: 10.1080/16078454.2024.2320006. Epub 2024 Feb 26. Hematology. 2024. PMID: 38407192 Clinical Trial.
115 results